Navigation Links
Moffitt researchers say race affect likelihood of finding suitable stem cell donor
Date:9/10/2012

Researchers at Moffitt Cancer Center and colleagues have published a study describing the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT).

The study appeared in the August issue of Bone Marrow Transplantation.

The success of HCT depends on finding cell donors who are closely matched genetically; as the degree of mismatching increases, the success of unrelated donor HCT falls accordingly. A patient's ideal donor is a genetically matched sibling.

The search for a perfectly matched donor for all groups takes time and affects the progression to transplantation. The National Marrow Donor Program estimates that the genetically matched donor rate is 90 percent for Caucasian patients, 70 percent for Hispanics and Asians, and 60 percent for those of African ancestry.

"Using unrelated adult donors to facilitate HCT has provided major opportunities for patients without a matched sibling donor. In fact, the rate of unrelated donors now exceeds the rate of related donor HCT," said Joseph Pidala, M.D., M.S., assistant member of Moffitt's Blood & Marrow Transplant Department and a member of the Immunology Program. "Using data available at Moffitt, we sought to describe the determinants of a successful, unrelated donor search and to explore the contribution of donor identification versus patient characteristics leading to successful transplantation outcome."

According to Pidala, many patients can achieve prolonged, condition-free survival after unrelated donor HCT. There is, however, a need to understand "modifiable factors" that limit access to unrelated donor HCT.

The researchers concluded that the difficulties in finding well-matched donors in some minority groups were likely related to the degree of genetic heterogeneity within those groups, as well as their underrepresentation in donor pools.

They concluded that when compared to Caucasians, African-Americans, Hispanics and Native Americans have greater difficulty in finding a suitably matched unrelated donor, and less likelihood of successfully reaching HCT. Other barriers to HCT include age and disease progression.

"This research speaks to the need for reducing the time from HCT consultation to donor identification and HCT," Pidala said. "Survival benefit for HCT is dependent upon finding a suitable donor in a timely manner and addressing modifiable barriers to reaching HCT."

"Our data are consistent with the expectation that if suitable unrelated donors could be more expeditiously identified, patient outcomes would improve, particularly for racial and ethnic minorities and for patients with better performance status," concluded Pidala and his colleagues. "Increased representation of ethnic minorities within unrelated donor registries will increase the likelihood of finding a suitable donor."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers study childhood melanoma characteristics
2. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
3. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
4. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
5. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
6. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
7. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
8. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
9. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
10. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
11. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Georgia (PRWEB) , ... March 28, 2017 , ... ... to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property ... a leader in the real estate valuation industry for more than 40 years. ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... 28, 2017 , ... Z-Medica, LLC, a leading developer and ... (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 ... efforts by the American College of Surgeons, U.S. Department of Defense, Department of ...
(Date:3/28/2017)... ... 28, 2017 , ... Award-winning medical group Allied Anesthesia today ... board chair for Orange County health care system CalOptima Friday. CalOptima announced its ... chair Mark Refowitz’s term, which runs through June 30 of this year, until ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... plans work, the Self-Funding Success website has recently developed and published an informational ... Plans ” was created based on common inquiries the site’s team of third ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Japan Patent Office (JPO) for the composition of ... (CTGF) for the treatment or prevention of fibrotic ... and proliferative retinopathy (Japanese Patent #: 6060071).  This ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology: